x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________ FORM 10-K __________________________________ (Mark One) OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number 001-39813 _____________________________ ...

TriSalus Life Sciences, Inc. (TLSI) shares soared 6.6% in the last trading session to close at $5.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.5% gain over the past four weeks.The recent surge in TriSalus Life Sciences Inc.'s shares can be attributed to its strong fourth quarter and full-year 2024 results, marked by 44% YoY revenue growth in the fourth quarter and 59% for the full year, driven by the TriNav Infusion Sys ...

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President & Chief Executive Officer James Young - Chief Financial Officer Richard Marshall - Medical Director Conference Call Participants Carl Burns - Northland Capital Markets Justin Walsh - JonesTrading Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity ...

TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.56 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.36 per share when it actually produced a loss of $0.40, delivering a surprise of -11.11%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.TriSalus Life Sciences, ...

Financial Results Announcement - TriSalus Life Sciences, Inc. announced preliminary unaudited financial results for the year and quarter ended December 31, 2024 [4] - The financial results were disclosed in a press release dated January 23, 2025, attached as Exhibit 99.1 to the Form 8-K [4] Form 8-K Filing Details - The information in Item 2.02 of the Form 8-K is furnished and not deemed "filed" under the Securities Exchange Act of 1934 [5] - The press release is incorporated by reference into the Form 8-K [4] Signatory Information - The report was signed by James Young, Chief Financial Officer of TriSalus Life Sciences, Inc., on January 23, 2025 [9]

I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wr ...

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Szela - President & Chief Executive Officer Sean Murphy - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity Justin Walsh - JonesTrading Operator Good morning, and welcome to TriSalus Science’s Third Quarter 2024 Earning ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-39813 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) De ...

Financial Performance - Reported Q3 2024 revenues of $7.3 million, representing a 42% year-over-year increase, and nine-month revenues of $21.2 million, up 66% year-over-year[1] - Revenue for the three months ended September 30, 2024, was $7,349,000, a 41.5% increase from $5,193,000 for the same period in 2023[20] - Gross profit for the nine months ended September 30, 2024, was $18,283,000, compared to $10,767,000 for the same period in 2023, representing a 70% increase[20] - Operating losses decreased to $8.7 million in Q3 2024 from $18.6 million in Q3 2023, due to increased sales and reduced expenses[12] - Net losses available to common stockholders were $2.4 million for Q3 2024, compared to $1.4 million in Q3 2023[13] - Net loss attributable to common stockholders for the three months ended September 30, 2024, was $3,202,000, compared to a loss of $1,883,000 for the same period in 2023[20] Market Expansion - Launched the TriNav® LV Infusion System and TriGuide™ Guiding Catheter, expanding access to the $375 million liver embolization market[1] - Initiated the PROTECT registry trial for treating multinodular goiters, potentially expanding the addressable market by $400 million[3] - The total addressable market is projected to exceed $1 billion in the U.S. with the new procedures utilizing the TriNav system[6] Guidance and Future Outlook - Provided 2025 guidance expecting over 50% annual sales growth and a reduction in operating expenses by over 20%[3] - Cash and cash equivalents totaled $11.3 million as of September 30, 2024, with expectations of positive cash flow in H2 2025[14] Operational Efficiency - Gross margins for Q3 2024 were 86%, compared to 89% in Q3 2023, attributed to increased factory volumes and operational efficiency[11] - Research and development expenses for the three months ended September 30, 2024, were $4,219,000, down from $9,506,000 in the same period of 2023, a decrease of 55.7%[20] - Sales and marketing expenses increased to $6,138,000 for the three months ended September 30, 2024, compared to $4,689,000 in the same period of 2023, an increase of 30.9%[20] Balance Sheet Highlights - Total assets as of September 30, 2024, were $27,477,000, an increase from $24,598,000 as of December 31, 2023[21] - Total liabilities decreased to $47,911,000 as of September 30, 2024, from $51,663,000 as of December 31, 2023[21] - The accumulated deficit increased to $(269,441,000) as of September 30, 2024, from $(249,504,000) as of December 31, 2023[22] - Cash and cash equivalents were $11,288,000 as of September 30, 2024, compared to $11,777,000 as of December 31, 2023[21] - The company reported a weighted average of 26,501,597 common shares outstanding for the three months ended September 30, 2024, compared to 13,173,422 shares for the same period in 2023[20]

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2024 Earnings Call Transcript August 15, 2024 9:00 AM ET Company Participants Jim Young - SVP, IR and Treasurer Mary Szela - President and CEO Alex Kim - SVP, Interventional Radiology Steven Katz - CMO Sean Murphy - CFO Conference Call Participants Justin Walsh - JonesTrading Operator Good morning, and welcome to TriSalus Science Second Quarter 2024 Earnings Conference Call. Currently, all participants are on listen-only mode. We will facilitate a question-and-a ...